NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $21,570 | -64.6% | 37,500 | +95.4% | 0.00% | -50.0% |
| Q3 2022 | $61,000 | -86.0% | 19,191 | -76.3% | 0.00% | -88.2% |
| Q1 2022 | $436,000 | +14.1% | 80,847 | +185.6% | 0.02% | +13.3% |
| Q4 2021 | $382,000 | -73.7% | 28,303 | -65.0% | 0.02% | -71.7% |
| Q3 2021 | $1,451,000 | -13.4% | 80,804 | -17.2% | 0.05% | +39.5% |
| Q2 2021 | $1,675,000 | +203.4% | 97,636 | +253.8% | 0.04% | +123.5% |
| Q1 2021 | $552,000 | -69.8% | 27,596 | -74.4% | 0.02% | -72.1% |
| Q4 2020 | $1,829,000 | – | 107,600 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |